Bringing a medical device to market in the United States starts with one pivotal decision: which FDA pathway to use. The agency does not treat a tongue depressor and an implantable defibrillator the same way, and choosing the wrong route can add months, or years, to a launch. Understanding the main FDA medical device pathways, 510(k), De Novo, and Premarket Approval (PMA), is one of the most valuable skills in regulatory affairs.

First, how the FDA classifies medical devices

Everything begins with risk. The FDA sorts devices into three classes, and the class drives the pathway, the evidence you must generate, and how long review will take:

• Class I (low risk): items such as bandages and examination gloves; most are exempt from premarket review.
• Class II (moderate risk): devices such as infusion pumps and many diagnostics; usually cleared through a 510(k).
• Class III (high risk): devices that support or sustain life, such as pacemakers and heart valves; these usually require a PMA.

510(k): clearance through substantial equivalence

The 510(k) is the most common route to market. Rather than proving safety and effectiveness from scratch, you demonstrate that your device is “substantially equivalent” to a legally marketed predicate device, supported by documented comparison and testing. Under the current MDUFA V agreement, the FDA aims to decide the large majority of 510(k)s within about 90 FDA days. It is the natural fit for Class II devices that have an established predicate.

De Novo: a route for novel, lower-risk devices

What if your device is genuinely new, with no predicate to point to, but is not high-risk enough to justify a PMA? The De Novo pathway was created for exactly this situation. It establishes a new classification for novel low-to-moderate-risk devices, with an FDA review goal in the range of 150 FDA days. A successful De Novo also creates a predicate that future devices can reference, opening the door for an entire product category.

Premarket Approval (PMA): the most rigorous route

PMA is the most demanding pathway, reserved for Class III devices that sustain life or carry significant risk. Unlike a 510(k), a PMA is a full scientific and regulatory review of safety and effectiveness, typically requiring clinical data, design validation, and an inspection of the manufacturing facility. Average total time to a decision runs to roughly 285 days. The bar is high because the stakes are.

How to choose the right pathway

Three questions usually point the way: How risky is the device? Does a predicate already exist? How novel is the technology? A sound regulatory strategy weighs those answers against timelines, cost, and the clinical evidence a company can realistically generate, and it documents the reasoning so the choice can be defended to the FDA.

Build the skills to navigate FDA pathways

Reading these pathways correctly is a core regulatory competency, and it is learnable. Aleph University’s Medical Device Regulation course walks through device classification, the 510(k), De Novo, and PMA routes, and the documentation each demands, as part of a broader catalog of continuing-education courses in medical devices, regulatory affairs, and quality. If you are still mapping the field, our guide to regulatory affairs careers is a good starting point.

Want to master FDA submission pathways? Request information and a custom quote for yourself or your team.